EUVIMEDEUVIMED entdecken
Open Access

Rosuvastatin Attenuates Progression of Atherosclerosis and Reduces Serum IL6 and CCL2 Levels in Apolipoprotein-E-deficient Mice

Diamantis I Tsilimigras, Kalliopi Thanopoulou, Maria Salagianni, Gerasimos Siasos, Evangelos Oikonomou, Despina D Perrea, Nikolaos Nirakis, Konstantinos Filis, Konstantinos Tsioufis, Dimitrios Tousoulis, Fragiska Sigala

In Vivo · 2023

DOI: 10.21873/invivo.13173 ↗

Kurz gefasst

Fachartikel in der Zeitschrift In Vivo, 2023. Verfasst von Diamantis I Tsilimigras und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Vascular Surgery, First Propedeutic Department of Surgery, Hippokration Hospital, National and Kapodistrian University of Athens, Athens,…. Hauptthemen laut MEDLINE: Atherosclerosis, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Plaque, Atherosclerotic. Die Arbeit wurde bisher 12-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AtherosclerosisHydroxymethylglutaryl-CoA Reductase InhibitorsPlaque, AtheroscleroticAnimalsHumansMiceApolipoproteinsApolipoproteins EChemokinesDiet, High-FatInterleukin-6LigandsLipidsMice, Inbred C57BLMice, KnockoutRosuvastatin CalciumTumor Necrosis Factor-alphaChemokine CCL2Azo Compounds

Stichwörter der Autor:innen

APOECCL2IL6Rosuvastatinatherosclerosismouse

Substanzen

ApolipoproteinsApolipoproteins EChemokinesHydroxymethylglutaryl-CoA Reductase InhibitorsInterleukin-6LigandsLipidsRosuvastatin CalciumTumor Necrosis Factor-alphaCCL2 protein, human

Autor:innen und Institutionen

  • Division of Vascular Surgery, First Propedeutic Department of Surgery, Hippokration Hospital, National and Kapodistrian University of Athens, Athens, Greece; diamantis.tsilimigras@gmail.com.
  • N.S. Christeas Laboratory for Experimental Surgery and Surgical Research National and Kapodistrian University of Athens, Athens, Greece.
  • Clinical, Experimental Surgery and Translational Research Center, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.
  • First Department of Cardiology, Hippokration Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece.
  • Division of Vascular Surgery, First Propedeutic Department of Surgery, Hippokration Hospital, National and Kapodistrian University of Athens, Athens, Greece.

Zitieren

APA

Tsilimigras, D. I., Thanopoulou, K., Salagianni, M., Siasos, G., Oikonomou, E., Perrea, D. D., Nirakis, N., Filis, K., Tsioufis, K., Tousoulis, D., & Sigala, F. (2023). Rosuvastatin Attenuates Progression of Atherosclerosis and Reduces Serum IL6 and CCL2 Levels in Apolipoprotein-E-deficient Mice. In Vivo. https://doi.org/10.21873/invivo.13173

Vancouver

Tsilimigras DI, Thanopoulou K, Salagianni M, Siasos G, Oikonomou E, Perrea DD, et al. Rosuvastatin Attenuates Progression of Atherosclerosis and Reduces Serum IL6 and CCL2 Levels in Apolipoprotein-E-deficient Mice. In Vivo. 2023. doi:10.21873/invivo.13173

BibTeX
@article{Tsilimigras2023,
  author = {Tsilimigras, Diamantis I and Thanopoulou, Kalliopi and Salagianni, Maria and Siasos, Gerasimos and Oikonomou, Evangelos and Perrea, Despina D and Nirakis, Nikolaos and Filis, Konstantinos and Tsioufis, Konstantinos and Tousoulis, Dimitrios and Sigala, Fragiska},
  title = {Rosuvastatin Attenuates Progression of Atherosclerosis and Reduces Serum IL6 and CCL2 Levels in Apolipoprotein-E-deficient Mice},
  journal = {In Vivo},
  year = {2023},
  doi = {10.21873/invivo.13173}
}
Kostenlos starten →